By Jennifer Chiou
New York, Nov. 2 - EyeGate Pharma announced it obtained $10 million of series B venture financing.
Innoven Partenaires led investors in the financing, which was co-led by Ventech.
The company said that this brings the total venture investment in the company to $14 million.
EyeGate Pharma said proceeds will go to bringing its clinical candidates for severe uveitis and glaucoma into the clinic in 2007 using its proprietary EyeGate II Delivery System.
Based in Waltham, Mass., EyeGate Pharma develops products to treat severe uveitis and glaucoma.
| Issuer: | EyeGate Pharma
|
| Issue: | Preferred stock
|
| Round: | Series B
|
| Amount: | $10 million
|
| Investors: | Innoven Partenaires (lead); Ventech (co-lead)
|
| Announcement date: | Nov. 2
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
